SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

26.55 -0.56

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

26.4

Max

26.7

Põhinäitajad
By Trading Economics
Sissetulek	-5.4M
Müük	27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	1.1M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	-13.21% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. märts 2026

Turustatistika
By TradingEconomics
Turukapital	1.3B
Eelmine avamishind	27.11
Eelmine sulgemishind	26.55

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. märts 2026, 17:33 UTC

Uudisväärsed sündmused

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27. märts 2026, 17:00 UTC

Uudisväärsed sündmused

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27. märts 2026, 16:03 UTC

Uudisväärsed sündmused

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

29. märts 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls Amid Rising Inflation Fears -- Market Talk

29. märts 2026, 23:46 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

29. märts 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

29. märts 2026, 23:23 UTC

Market Talk

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

29. märts 2026, 22:34 UTC

Market Talk

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

29. märts 2026, 22:09 UTC

Market Talk

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

29. märts 2026, 21:06 UTC

Market Talk

Uudisväärsed sündmused

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

29. märts 2026, 21:03 UTC

Market Talk

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

29. märts 2026, 21:01 UTC

Market Talk

Uudisväärsed sündmused

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

29. märts 2026, 09:30 UTC

Omandamised, ülevõtmised, äriostud

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

28. märts 2026, 08:20 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 19:16 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27. märts 2026, 19:07 UTC

Market Talk

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27. märts 2026, 19:04 UTC

Market Talk

Gold Rises But Can't Finish the Week Positive -- Market Talk

27. märts 2026, 19:03 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

27. märts 2026, 19:02 UTC

Market Talk

Uudisväärsed sündmused

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27. märts 2026, 18:12 UTC

Market Talk

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27. märts 2026, 17:36 UTC

Uudisväärsed sündmused

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27. märts 2026, 17:34 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27. märts 2026, 17:29 UTC

Market Talk

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27. märts 2026, 16:38 UTC

Market Talk

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27. märts 2026, 16:32 UTC

Market Talk

Uudisväärsed sündmused

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27. märts 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 15:43 UTC

Market Talk

Uudisväärsed sündmused

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27. märts 2026, 15:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. märts 2026, 15:25 UTC

Market Talk

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

-13.21% langus

12 kuu keskmine prognoos

Keskmine 23 EUR -13.21%

Kõrge 23 EUR

Madal 23 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.